Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582057 | 0.79 | KMT2A (0.61) | CYP2D6CYP2C19CYP2C9POLBKMT2A | |
| SCHEMBL9678330 | 0.78 | CRBN (0.46) | SCN9AKDM4ECRBNALDH1A1GRM5 | |
| SCHEMBL9677180 | 0.77 | CRBN (0.42) | CYP2D6CYP2C9POLBKMT2ASCN9A | |
| SCHEMBL9677162 | 0.77 | CRBN (0.42) | CYP2D6CYP2C9POLBKMT2ASCN9A | |
| SCHEMBL2964066 | 0.75 | DRD2 (0.57) | CYP2D6CYP2C19CYP2C9POLBKMT2A | |
| SCHEMBL5054210 | 0.74 | ALDH1A1 (0.47) | CYP2C9SCN9ACYP3A4KDM4EHSD17B10 | |
| SCHEMBL12427186 | 0.73 | CRBN (0.53) | SCN9AKDM4EHSD17B10HPGDCRBN | |
| SCHEMBL4921733 | 0.73 | CRBN (0.41) | SCN9AKDM4ECRBNALDH1A1GRM5 | |
| SCHEMBL5174282 | 0.72 | NPSR1 (0.71) | CYP2C9POLBKMT2ACYP3A4KDM4E | |
| SCHEMBL1568127 | 0.71 | KDM4C (0.53) | KDM4ECRBNALDH1A1NPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791843-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-1791843-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-1606264-B1 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-1606264-B1 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-05-02 | — | — | EP | disclosed |
| US-7659300-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659300-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659300-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090054408-A1 | Monocyclic anilide spirolactam cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090054408-A1 | Monocyclic anilide spirolactam cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090054408-A1 | Monocyclic anilide spirolactam cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-02-26 | — | — | US | disclosed |
| EP-1606264-A4 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1791843-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| US-7192954-B2 | Monocyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192954-B2 | Monocyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192954-B2 | Monocyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20060148779-A1 | Monocyclic anilide spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-07-06 | — | — | US | disclosed |
| WO-2006029153-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1606264-A1 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004083187-A1 | MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148779-A1 | Monocyclic anilide spirohydantoin cgrp receptor antagonists | CALCRL, CALCR, CCKAR | CYP2D6 1997/4885CYP2C19 1934/4885CYP2C9 1710/4885 |
| US-20090054408-A1 | Monocyclic anilide spirolactam cgrp receptor antagonists | BDKRB1, BDKRB2, CALCRL | CYP2D6 1253/4885CYP2C19 1442/4885CYP2C9 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.